Table 1.

Patient characteristics

All Patients (n=105)No Hemodialysis-Induced Regional LV Dysfunction (n=76)Hemodialysis-Induced Regional LV Dysfunction (n=29)P Value
Median age in years (IQR)66 (51–75)64 (50–75)69 (58–78)0.18
Male sex (n)68 (64.8%)45 (59.2%)23 (79.3%)0.05
Median dialysis vintage in months (IQR)21.4 (7.8–48.5)24 (8.3–48.3)18.4 (5.5–49.7)0.69
Diabetes (n)23 (21.9%)19 (25.0%)4 (13.8%)0.28
Hypertension (n)84 (80.0%)61 (80.3%)23 (79.3%)0.95
Cardiovascular history (n)23 (21.9%)15 (19.7%)8 (27.6%)0.39
Median BMI (kg/m2; IQR)25.2 (23.0–28.1)25.2 (22.6–28.3)25.2 (23.2–27.8)0.88
Primary renal disease (n)
 Hypertension17 (16.2%)12 (15.8%)5 (17.2%)0.86
 Diabetes13 (12.4%)11 (14.5%)2 (6.9%)0.29
 ADPKD14 (13.3%)10 (13.6%)4 (13.8%)0.93
 FSGS10 (9.5%)8 (10.5%)2 (6.9%)0.57
 IgA nephropathy4 (3.8%)4 (5.3%)00.21
 Chronic pyelonephritis1 (1.0%)1 (1.3%)00.54
 Glomerulonephritis13 (12.4%)10 (13.2%)3 (10.3%)0.70
 Other diagnoses16 (15.2%)10 (13.2%)6 (20.6%)0.21
 Unknown17 (16.2%)10 (13.2%)7 (24.1%)0.17
Medication (n)
 Aspirin57 (54.3%)46 (60.5%)11 (37.9%)0.04
 CCB14 (13.3%)12 (15.8%)2 (6.9%)0.23
  β-Blocker60 (57.1%)45 (59.2%)15 (51.7%)0.49
 ACE inhibitor10 (9.5%)8 (10.5%)2 (6.9%)0.57
 ARB14 (13.3%)10 (13.2%)4 (13.8%)0.34
 Statin20 (19.1%)14 (18.4%)6 (20.7%)0.79
Median SGA (IQR)6 (6–7)6 (6–7)6 (5–7)0.77
Hematocrit (mean ± SD)35.0±3.735.1±4.034.6±3.00.53
Median albumin (g/L; IQR)39 (37–41)39 (37–42)39 (37–41)0.64
Median phosphate (mmol/L; IQR)1.7 (1.3–1.9)1.7 (1.3–2.0)1.6 (1.4–1.9)0.92
Median Kt/V (IQR)4.3 (3.8–4.7)4.3 (3.8–4.7)4.0 (3.9–4.5)0.36
Ultrafiltration volume (L; mean ± SD)2.6±0.82.5±0.72.60±0.90.83
Ultrafiltration rate (ml/kg per hour; mean ± SD)8.5±2.68.6±2.58.3±3.00.59
LV mass index (g/m2; mean ± SD)93.3±26.089.9±24.6101.7±27.90.05
LVH (n)25 (23.8%)19 (25%)6 (20.7%)0.64
Median predialysis WMSI (IQR)1.00 (1.00–1.13)1.00 (1.00–1.03)1.21 (1.06–1.44)<0.001
Predialysis LVEF (mean ± SD)50.0%±10.4%51.8%±9.5%45.3%±10.4%0.008
  • LV, left ventricular; IQR, interquartile range; BMI, body mass index; ADPKD, adult dominant polycystic kidney disease; FSGS, focal segmental glomerulosclerosis; CCB, calcium channel blocker; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; SGA, subjective global assessment; LVH, LV hypertrophy; WMSI, wall motion score index; LVEF, LV ejection fraction.